Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.

Borin MT, Lo A, Barnes CN, Pendyala S, Bourdet DL.

Int J Chron Obstruct Pulmon Dis. 2019 Oct 8;14:2305-2318. doi: 10.2147/COPD.S203709. eCollection 2019.

2.

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.

Hallow KM, Lo A, Beh J, Rodrigo M, Ermakov S, Friedman S, de Leon H, Sarkar A, Xiong Y, Sarangapani R, Schmidt H, Webb R, Kondic AG.

Am J Physiol Regul Integr Comp Physiol. 2014 May;306(9):R647-62. doi: 10.1152/ajpregu.00039.2013. Epub 2014 Feb 5.

3.

Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.

Ou YC, Lo A, Lee B, Liu P, Kimura K, Eary C, Hopkins A.

J Clin Pharmacol. 2013 Nov;53(11):1112-20. doi: 10.1002/jcph.157. Epub 2013 Aug 29.

PMID:
23913679
4.

Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.

Dahari H, Lo A, Ribeiro RM, Perelson AS.

J Theor Biol. 2007 Jul 21;247(2):371-81. Epub 2007 Mar 14.

5.

Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1.

Crise B, Li Y, Yuan C, Morcock DR, Whitby D, Munroe DJ, Arthur LO, Wu X.

J Virol. 2005 Oct;79(19):12199-204.

6.
7.
8.

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.

Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, Coalter VJ, Poore B, Kiser RF, Imming RJ, Scarzello AJ, Henderson LE, Alvord WG, Hirsch VM, Benveniste RE, Arthur LO.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):772-87.

PMID:
15307924
9.

Theoretical simulation of K(+)-based mechanisms for regulation of capillary perfusion in skeletal muscle.

Lo A, Fuglevand AJ, Secomb TW.

Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H833-40.

10.

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7. Epub 2003 Dec 10.

12.

Oxygen delivery to skeletal muscle fibers: effects of microvascular unit structure and control mechanisms.

Lo A, Fuglevand AJ, Secomb TW.

Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H955-63. Epub 2003 May 8.

13.
14.

Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge.

Lifson JD, Piatak M Jr, Rossio JL, Bess J Jr, Chertova E, Schneider D, Kiser R, Coalter V, Poore B, Imming R, Desrosiers RC, Henderson LE, Arthur LO.

J Med Primatol. 2002 Aug;31(4-5):205-16.

PMID:
12390543
15.

Dynamics of hepatitis B virus infection.

Ribeiro RM, Lo A, Perelson AS.

Microbes Infect. 2002 Jul;4(8):829-35. Review.

PMID:
12270730
16.

Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, Moss B.

J Virol. 2002 Aug;76(15):7863-7.

17.

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO.

J Virol. 2002 Jun;76(11):5315-25.

18.

Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation.

Center RJ, Schuck P, Leapman RD, Arthur LO, Earl PL, Moss B, Lebowitz J.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14877-82.

20.

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.

Buseyne F, Le Gall S, Boccaccio C, Abastado JP, Lifson JD, Arthur LO, Rivière Y, Heard JM, Schwartz O.

Nat Med. 2001 Mar;7(3):344-9.

PMID:
11231634
21.

Partial activation and induction of apoptosis in CD4(+) and CD8(+) T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1.

Esser MT, Bess JW Jr, Suryanarayana K, Chertova E, Marti D, Carrington M, Arthur LO, Lifson JD.

J Virol. 2001 Feb;75(3):1152-64.

22.

Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Gorelick RJ, Benveniste RE, Lifson JD, Yovandich JL, Morton WR, Kuller L, Flynn BM, Fisher BA, Rossio JL, Piatak M Jr, Bess JW Jr, Henderson LE, Arthur LO.

J Virol. 2000 Dec;74(24):11935-49.

23.

Mucosal challenge of Macaca nemestrina with simian immunodeficiency virus (SIV) following SIV nucleocapsid mutant DNA vaccination.

Gorelick RJ, Lifson JD, Yovandich JL, Rossio JL, Piatak M Jr, Scarzello AJ, Knott WB, Bess JW Jr, Fisher BA, Flynn BM, Henderson LE, Arthur LO, Benveniste RE.

J Med Primatol. 2000 Aug;29(3-4):209-19.

PMID:
11085583
24.

Characterization of the block in replication of nucleocapsid protein zinc finger mutants from moloney murine leukemia virus.

Gorelick RJ, Fu W, Gagliardi TD, Bosche WJ, Rein A, Henderson LE, Arthur LO.

J Virol. 1999 Oct;73(10):8185-95.

25.
26.

Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.

Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH.

Nature. 1999 Feb 4;397(6718):436-41.

PMID:
9989410
27.

Probing the topography of HIV-1 nucleocapsid protein with the alkylating agent N-ethylmaleimide.

Chertova EN, Kane BP, McGrath C, Johnson DG, Sowder RC 2nd, Arthur LO, Henderson LE.

Biochemistry. 1998 Dec 22;37(51):17890-7.

PMID:
9922156
28.

Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivo.

Gorelick RJ, Benveniste RE, Gagliardi TD, Wiltrout TA, Busch LK, Bosche WJ, Coren LV, Lifson JD, Bradley PJ, Henderson LE, Arthur LO.

Virology. 1999 Jan 20;253(2):259-70.

29.

Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.

Arthur LO, Bess JW Jr, Chertova EN, Rossio JL, Esser MT, Benveniste RE, Henderson LE, Lifson JD.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S311-9.

PMID:
9814959
30.

HIV-1 envelope gp120 inhibits the monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation.

Wang JM, Ueda H, Howard OM, Grimm MC, Chertov O, Gong X, Gong W, Resau JH, Broder CC, Evans G, Arthur LO, Ruscetti FW, Oppenheim JJ.

J Immunol. 1998 Oct 15;161(8):4309-17.

31.

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD.

J Virol. 1998 Oct;72(10):7992-8001.

32.
33.

Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus.

Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE.

J Virol. 1998 Apr;72(4):2962-8.

34.

Identification of highly attenuated mutants of simian immunodeficiency virus.

Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP.

J Virol. 1998 Feb;72(2):1431-7.

35.

Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.

Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM Jr, Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS Jr, Arthur LO, Mizutani S, Davis A, Hung PP, Gallo RC, Eichberg J, Robert-Guroff M.

Nat Med. 1997 Jun;3(6):651-8.

PMID:
9176492
36.

Wild-type and mutant HIV type 1 nucleocapsid proteins increase the proportion of long cDNA transcripts by viral reverse transcriptase.

Drummond JE, Mounts P, Gorelick RJ, Casas-Finet JR, Bosche WJ, Henderson LE, Waters DJ, Arthur LO.

AIDS Res Hum Retroviruses. 1997 May 1;13(7):533-43.

PMID:
9135871
37.
38.

Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO.

Virology. 1997 Mar 31;230(1):134-44.

39.

Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.

Ott DE, Coren LV, Kane BP, Busch LK, Johnson DG, Sowder RC 2nd, Chertova EN, Arthur LO, Henderson LE.

J Virol. 1996 Nov;70(11):7734-43.

40.

Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein.

Rein A, Ott DE, Mirro J, Arthur LO, Rice W, Henderson LE.

J Virol. 1996 Aug;70(8):4966-72.

41.

Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.

Shibata R, Siemon C, Cho MW, Arthur LO, Nigida SM Jr, Matthews T, Sawyer LA, Schultz A, Murthy KK, Israel Z, Javadian A, Frost P, Kennedy RC, Lane HC, Martin MA.

J Virol. 1996 Jul;70(7):4361-9.

43.

HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis.

Rossio JL, Bess J Jr, Henderson LE, Cresswell P, Arthur LO.

AIDS Res Hum Retroviruses. 1995 Dec;11(12):1433-9.

PMID:
8679286
44.

Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC 2nd, Arthur LO, Henderson LE.

Science. 1995 Nov 17;270(5239):1194-7.

PMID:
7502043
45.

Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.

Ott DE, Coren LV, Johnson DG, Sowder RC 2nd, Arthur LO, Henderson LE.

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1003-6.

PMID:
8554896
46.

Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Shibata R, Hoggan MD, Broscius C, Englund G, Theodore TS, Buckler-White A, Arthur LO, Israel Z, Schultz A, Lane HC, et al.

J Virol. 1995 Jul;69(7):4453-62.

47.

Human immunodeficiency virus.

Arthur LO, Henderson LE, Benveniste RE.

N Engl J Med. 1995 Jun 22;332(25):1719. No abstract available.

PMID:
7760882
48.

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Arthur LO, Bess JW Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE.

J Virol. 1995 May;69(5):3117-24.

49.
50.

DNA binding properties of the zinc-bound and zinc-free HIV nucleocapsid protein: supercoiled DNA unwinding and DNA-protein cleavable complex formation.

Priel E, Aflalo E, Seri I, Henderson LE, Arthur LO, Aboud M, Segal S, Blair DG.

FEBS Lett. 1995 Mar 27;362(1):59-64.

Supplemental Content

Loading ...
Support Center